The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Putilina M.V.

Pirogov Russian National Research Medical University

Teplova N.V.

Pirogov Russian National Research Medical University

Possibilities of individual choice of NSAIDs on the example of the oxicam class, taking into account clinical and pharmacological characteristics

Authors:

Putilina M.V., Teplova N.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7): 36‑41

DOI: 10.17116/jnevro202212207136

Read: 12459 times

Contact the author
Table of contents

POSSIBILITIES OF INDIVIDUAL CHOICE OF NSAIDS ON THE EXAMPLE OF THE OXICAM CLASS, TAKING INTO ACCOUNT CLINICAL AND PHARMACOLOGICAL CHARACTERISTICS
POSSIBILITIES OF INDIVIDUAL CHOICE OF NSAIDS ON THE EXAMPLE OF THE OXICAM CLASS, TAKING INTO ACCOUNT CLINICAL AND PHARMACOLOGICAL CHARACTERISTICS

To cite this article:

Putilina MV, Teplova NV. Possibilities of individual choice of NSAIDs on the example of the oxicam class, taking into account clinical and pharmacological characteristics. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7):36‑41. (In Russ.)
https://doi.org/10.17116/jnevro202212207136

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Clinical characteristics of pain syndromes in dental practice among patients with chro­nic kidney disease. Stomatology. 2026;(4):34-39
Abstract:

Nonsteroidal anti-inflammatory drugs (NSAIDs) are traditionally used to relieve pain syndromes. The class of NSAIDs includes oxicams (meloxicam, tenoxicam, lornoxicam) — drugs with pronounced analgesic and anti-inflammatory effects. Oxicams have common properties of the class, but at the same time, due to structural differences from all other NSAIDs, they differ in a number of clinical and pharmacological characteristics, knowledge of which will help to individualize the choice of the drug.

Keywords:

pain syndromes
oxicams
Meloxicam
Tenoxicam
Lornoxicam
NSAIDs

Authors:

Putilina M.V.

Pirogov Russian National Research Medical University

Teplova N.V.

Pirogov Russian National Research Medical University

Received:

09.06.2022

Accepted:

14.06.2022

Close metadata

References:

  1. Nicholas M, Vlaeyen JWS, Rief W, et al. IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain. 2019;160(1):28-37.  https://doi.org/10.1097/j.pain.0000000000001390
  2. Stevans JM, Delitto A, Khoja SS, et al. Risk Factors Associated With Transition From Acute to Chronic Low Back Pain in US Patients Seeking Primary Care. JAMA Netw Open. 2021;4(2):e2037371. https://doi.org/10.1001/jamanetworkopen.2020.37371
  3. Putilina MV, Naumov AV, Teplova NV. Chronic pain syndromes. Medical Alphabet. 2021;8(3):12-17. (In Russ.).
  4. Rational use of non-steroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):1-29. (In Russ.). https://doi.org/10.14412/1995-4484-2018-1-29
  5. Ramanathan S, Hibbert P, Wiles L, et al. What is the association between the presence of comorbidities and the appropriateness of care for low back pain? A population-based medical record review study. BMC Musculoskelet Disord. 2018;19(1):391.  https://doi.org/10.1186/s12891-018-2316-z
  6. Putilina MV. Patient comorbidity in clinical practice. Consilium Medicum. 2017;19(2):71-79. (In Russ.).
  7. Dong L, Anderson AJ, Malkows MG. Arg-513 and Leu-531 Are Key Residues Governing Time-Dependent Inhibition of Cyclooxygenase-2 by Aspirin and Celebrex. Biochemistry. 2019;58(38):3990-4002. https://doi.org/10.1021/acs.biochem.9b00659
  8. Ullah N, Huang Z, Sanaee F, et al. NSAIDs do not require the presence of a carboxylic acid to exert their anti-inflammatory effect — why do we keep using it? J Enz Inhibition Med Chem. 2016;31(6):1018-1028. https://doi.org/10.3109/14756366.2015.1088840
  9. Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life. 2014;66(12):803-811.  https://doi.org/10.1002/iub.1334
  10. Yakhno NN, Kukushkin ML, Churyukanov MV, et al. The results of open multicentral study «Meridian» for assessment of pain syndromes prevalence in ambulatory and therapeutic preferences of physicians. Russian Journal of Pain. 2012;3-4:10-14. (In Russ.).
  11. Lucido MJ, Orlando BJ, Vecchio AJ, et al. Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products with Reversed Stereochemistry. Biochemistry. 2016;55(8):1226-1238. https://doi.org/10.1021/acs.biochem.5b01378
  12. Andryukov KV, Korkodinova LM. Search for compounds with analgesic activity using molecular docking in «structure-activity» studies on COX1 and 2 enzymes in the series of substituted anthranilic acids International. Journal of Applied and Basic Research. 2019;12-1:60-64. (In Russ.).
  13. Tasaki Y, Yamamoto J, Omura T, et al. Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity. Eur J Pharmacol. 2012;676:57-63.  https://doi.org/10.1016/j.ejphar.2011.11.046
  14. Tasaki Y, Yamamoto J, Omura T, et al. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson’s disease model. Neurosci Lett. 2012;521:15-19.  https://doi.org/10.1016/j.neulet.2012.05.045
  15. Omura T, Sasaoka M, Hashimoto G, et al. Oxicam-derived non-steroidal anti-inflammatory drugs suppress 1-methyl-4-phenyl pyridinium-induced cell death via repression of endoplasmic reticulum stress response and mitochondrial dysfunction in SH-SY5Y cells. Biochem Biophys Res Com. 2018;503(4):2963-2969. https://doi.org/10.1016/j.bbrc.2018.08.078
  16. Karateev AE. Meloxicam: The golden mean of nonsteroidal anti-inflammatory drugs. Terapevticheskii Arkhiv. 2014;86(5):99-105. (In Russ.).
  17. Instructions for the medical use of the drug Artrozan tablets RU LS-001013 dated 05/31/2010. Artrozan solution for intramuscular injection RU LP — No. 000537 dated 02.01.2022. (In Russ.).
  18. Lopez-Garcia JA, Laird JM. Central antinociceptive effects of meloxicam on rat spinal cord in vitro. Neuroreport. 1998;9(4):647-651.  https://doi.org/10.1097/00001756-199803090-00016
  19. Khairnar A, Marchand F, Vidal A, et al. 99mTc-NTP 15-5 Imaging for Cartilage Involvement in Experimental Rheumatoid Arthritis: Comparison with Routinely Used Molecular Imaging Methods and Sensitivity to Chronic Nonsteroidal Antiinflammatory Drug Treatment. J Nucl Med. 2015;56(5):798-804.  https://doi.org/10.2967/jnumed.114.151415
  20. Nagy E, Vajda E, Vari C, et al. Meloxicam ameliorates the cartilage and subchondral bone deterioration in monoiodoacetate-induced rat osteoarthritis. Peer J. 2017;5:e3185. https://doi.org/10.7717/peerj.3185
  21. Sas EI, Grinevich VB. Safe use of meloxicam in clinical practice. Med Sovet. 2019;1:46-50. (In Russ.). https://doi.org/10.21518/2079-701X-2019-1-46-50
  22. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large Scale International Study Safety Assessment. Br J Rheumatol. 1988;37:937-945. 
  23. Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability on the selective cyclooxygenase (COX)-2 inhibitor meloxicam, compared with piroxicam: results of the Safety and Efficacy Large scale Evalution of COX inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998;37:946-951. 
  24. Lapeyre-Mestre M, Grolleau S, Montastruc JL. Association Française des Centres Régionaux de Pharmacovigilance (CRPV) Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002—2006. Fundam Clin Pharmacol. 2013;27(2):223-230. 
  25. Singh G, Lanes S, Triadafilopoulos G. Risk upper gastrointestinal/cardiovascular thromboembolic complications with meloxicam. Am J Med. 2004;117(2):100-106. 
  26. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015;23(1):1-16.  https://doi.org/10.1007/s10787-014-0225-9
  27. Karateev AE, Lila AM, Pogozheva EYu, et al. Factors influencing the efficacy of nonsteroidal anti-inflammatory drugs for acute low back pain. The results of the multicenter observational «CARAMBOL» (Clinical Analysis of Results of Analgesia by Meloxicam and its Safety in Acute Lumbodynia) study. Modern Rheumatology. 2019;13(2):31-37. (In Russ.). https://doi.org/10.14412/1996-7012-2019-2-31-37
  28. Putilina MV, Ivanova MP, Petrikeyeva AE, et al. Difficulties in diagnosing sacroiliitis in young patients. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(8):117-126. (In Russ.). https://doi.org/10.17116/jnevro2020120081117
  29. Putilina MV, Petrikeeva AE, Ariskina IG. Back pain associated with a new coronavirus infection COVID-19. Russian Journal of Pain. 2022;20(1):42-47. (In Russ.). https://doi.org/10.17116/pain20222001142
  30. Barsukova NA, Pyshnograeva LV. Experience in the clinical use of the drug Artrozan in patients with osteoarthritis and concomitant erosive and ulcerative lesions of the gastrointestinal tract. Pharmateka. 2007;12:1-3. (In Russ.).
  31. Zaripova AI, Khuzina GR, Sakovets TG. Cervicogenic headache: differential diagnostic and pharmacotherapeutic aspects. Modern Medicine. Neurology. Rehabilitation. 2020;1(17):71-78. (In Russ.).
  32. Jahr JS, Searle S, McCallum S, et al. Platelet Function: Meloxicam Intravenous in Whole Blood Samples From Healthy Volunteers. Clin Pharm Drug Devel. 2020;9:841-848.  https://doi.org/10.1002/cpdd.772
  33. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, et al. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41(4):458-461.  https://doi.org/10.1093/rheumatology/41.4.458
  34. Rinder HM, Tracey JB, Souhrada M, et al. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial. J Clin Pharmacol. 2002;42(8):881-886.  https://doi.org/10.1177/009127002401102795
  35. Putilina MV, Shabalina NI, Grishin DV, et al. Meloxicame effect on coagulogram parameters in patients with back pain after suffering a coronovirus infection COVID-19. Rmj. 2022;4:11-14. (In Russ.).
  36. Busch U, Heinzel G, Narjes H, Nehmiz G. Interaction of meloxicam with cimetidine, Maalox, or aspirin. J Clin Pharmacol. 1996;36(1):79-84.  https://doi.org/10.1002/j.1552-4604.1996.tb04155.x
  37. Spektor G, Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk — where are we now? Nat Clin Pract Cardiovasc Med. 2005;2(6):290-300.  https://doi.org/10.1038/ncpcardio0214
  38. Altman R, Luciardi H, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation. 2002;106(2):191-195. 
  39. Nilsen OG. Clinical pharmacokinetics of tenoxicam. Clin Pharmacokinet. 1994;26(1):16-43. 
  40. Elshafie HS, Sadeek SA, Camele I, et al. Biological and Spectroscopic Investigations of Tenoxicam and Phenthroline Metal Complexes. Molecules. 2020;25(5):1027. https://doi.org/10.3390/molecules25051027
  41. Karateev AE. Non-steroidal anti-inflammatory drugs use in clinical practice: new opportunities. Consilium Medicum. 2018;2(9):88-94. (In Russ.).
  42. Sanel S, Arpaz O, Unay K, et al. Comparison of intra-articular bupivacaine-morphine with bupivacaine-tenoxicam combinations on post-operative analgesia in patients with arthros-copic meniscectomy: a prospective, randomised study. Int Orthop. 2016;40(3):601-605.  https://doi.org/10.1007/s00264-015-2990-5
  43. Ahmed MO, Al-Badr AA. Lornoxicam, Comprehensive Profile, Profiles of Drug Substances, Excipients and Related Methodology. Profiles of Drug Substances, Excipients and Related Methodology. 2011;36:205-237. 
  44. Parada L, Marstein JP, Danilov A. Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain. Pain Manag. 2016;6(5):445-454.  https://doi.org/10.2217/pmt.16.7
  45. Naumov AV, Tkacheva ON, Khovasova NO. Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular risk. Ter Arkhiv. 2019;91(1):108-113. (In Russ.). https://doi.org/10.26442/00403660.2019.01.000039
  46. Radhofer-Welte S, Dittrich P, Simin M, et al. Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular injection: a randomized, open-label, crossover phase I study in healthy volunteers. Clin Drug Investig. 2008;28:345-351. 
  47. Gromova OA, Torshin IYu, Putilina MV, et al. Chemoreactomic analysis of the central mechanisms of action of non-steroidal anti-inflammatory drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(1):70-77. (In Russ.). https://doi.org/10.17116/jnevro202012001170
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.